Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | KDM5A | P29375 | 3/20 | 0.39 |
| ▸ | POLR1A | O95602 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2199731 | 0.90 | KDM5A (0.42) | JAK1KDM5APOLR1AGFERKMT2A | |
| SCHEMBL2197825 | 0.89 | JAK1 (0.38) | JAK1KDM5APOLR1AGFERKMT2A | |
| SCHEMBL2201424 | 0.88 | GRM5 (0.38) | JAK1KDM5APOLR1AGFERKMT2A | |
| SCHEMBL2202128 | 0.88 | PIK3CA (0.38) | JAK1KDM5APOLR1AGFERKMT2A | |
| SCHEMBL12510317 | 0.87 | KDM5A (0.45) | JAK1KDM5APOLR1AGFERKMT2A | |
| SCHEMBL2199647 | 0.87 | PIK3CA (0.38) | JAK1KDM5APOLR1AGFERKMT2A | |
| SCHEMBL2198072 | 0.86 | KDM5A (0.41) | JAK1KDM5APOLR1AGFERKMT2A | |
| SCHEMBL2199738 | 0.85 | JAK1 (0.40) | JAK1KDM5APOLR1AGFERKMT2A | |
| SCHEMBL2199126 | 0.85 | PIK3CA (0.41) | JAK1KDM5APOLR1AGFERKMT2A | |
| SCHEMBL12510461 | 0.84 | JAK1 (0.41) | JAK1KDM5APOLR1AGFERKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977358-B2 | Pyrazol derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-07-12 | — | — | US | disclosed |
| EP-2182953-A2 | NEW PYRAZOL DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2010-05-12 | — | — | EP | disclosed |
| US-20090029963-A1 | PYRAZOL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-29 | — | — | US | disclosed |
| WO-2009013211-A2 | NEW PYRAZOL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029963-A1 | PYRAZOL DERIVATIVES | CCR1, CCR3, CCRL2 | JAK1 553/4885KDM5A 2215/4885POLR1A 1494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.